Mersolat-D

Quick links to important sections

Mersolat-D

Treatment option: Hypertension, Glaucoma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mersolat-D

Quick Facts

Property Description
Active Ingredient Dorzolamide hydrochloride
Form Ophthalmic solution (Eye drops)
Pharmacological Class Topical Carbonic Anhydrase Inhibitor (CAI)
Common Use Lowering elevated intraocular pressure (IOP)
Origin Synthetic sulfonamide derivative

Mersolat-D: Identity and Pharmacological Classification

Mersolat-D is a specific brand of prescription ophthalmic solution administered as eye drops, whose single active component is Dorzolamide hydrochloride, a synthetic compound. This compound defines the product as a Topical Carbonic Anhydrase Inhibitor (CAI), a pharmacological classification consistently supported by authoritative studies. As a key differentiating factor, Mersolat-D is formulated for localized therapy for pressure imbalances in the eyes, which underscores its specialization within topical ophthalmology. The formulation is a sterile, buffered aqueous solution intended for direct topical ophthalmic application, ensuring localized action rather than systemic effects. Mersolat-D functions exclusively as a single-agent product (monotherapy).

What is the General Purpose of Dorzolamide?

The fundamental purpose of Mersolat-D is to serve as an antiglaucoma agent aimed at achieving a sustained reduction in pressure inside the eye, a clinical necessity that is widely recognized in medical guidelines. Its therapeutic action focuses on the enzyme Carbonic Anhydrase II within the ciliary processes to suppress the formation of aqueous humor, the fluid critical to ocular homeostasis. By inhibiting this key enzyme, the medication effectively slows the rate of fluid secretion. This localized physiological action directly lowers elevated intraocular pressure (IOP), which is the cornerstone of its clinical utility for maintaining the long-term health of the eye's internal structures.

Regulatory References

  1. (MedlinePlus, NIH)

What side effects are possible with Mersolat-D?

Possible Side Effects and Safety Information

The safety profile of Mersolat-D (Dorzolamide hydrochloride) is characterized by classifying adverse reactions based on their frequency as documented in official regulatory sources. The most very common adverse reactions are ocular burning and stinging, reflecting the medication's topical application.

Frequency-Classified Adverse Reactions

Classification Representative Adverse Reactions
Very Common Ocular burning and stinging
Common Headache, superficial punctate keratitis, blurred vision, bitter taste, asthenia (weakness), localized allergic reactions of the eyelids
Rare Transient myopia, corneal edema, dizziness, paresthesia, nephrolithiasis

Systemic and Serious Adverse Reactions

Adverse effects are documented across several System-Organ Classes, including Eye Disorders, Nervous System Disorders, and Gastrointestinal Disorders. Due to the drug’s sulfonamide structure, systemic absorption carries a documented, though rare, risk of serious adverse reactions. These clinically significant events listed in regulatory documents include Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, and blood disorders such as aplastic anemia.

Safety Constraints and Special Populations

The official labeling includes specific limitations based on systemic absorption. Use of this medication is not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min). Caution is also advised for use in patients with hepatic impairment, as specific studies have not been conducted in this population. Furthermore, regulatory documents do not recommend the concurrent use of Mersolat-D with oral carbonic anhydrase inhibitors due to the potential for additive systemic effects.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Dorzolamide hydrochloride (Mersolat-D) may result in specific physiological changes. These documented manifestations primarily include the development of acidosis and significant electrolyte imbalance, alongside possible central nervous system (CNS) effects.

Due to the systemic absorption of this sulfonamide derivative, there is a documented, though rare, risk of severe systemic reactions characteristic of sulfonamides, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, which have been reported in regulatory contexts.

Overdose Management and Help-Seeking Official Regulatory Statement
Urgent Action Required Seek medical care right away if overdose is suspected or if the contents of the container are ingested, and contact a Poison Control center immediately.
Management Type Treatment is defined as symptomatic and supportive.
Monitoring Requirements Monitoring of serum electrolyte levels (specifically potassium) and blood pH levels is required during management.
Population Note The product is not recommended in patients with severe renal impairment (creatinine clearance [ CrCl] < 30 mL/min) due to the risk of systemic accumulation, which may elevate overdose risk.

The official profile states that no specific antidote is known. The actions mandated by regulators emphasize immediate professional intervention and specific laboratory monitoring to address the documented physiological imbalances.

Therapeutic Uses of Mersolat-D

Mersolat-D is an eye medication that combines two active components. This medication is generally applied in addressing conditions marked by elevated intraocular pressure (IOP). The documented therapeutic use is relevant in conditions characterized by periods of heightened symptoms of elevated IOP, such as open-angle glaucoma and ocular hypertension.

The medication is commonly used when symptoms that create noticeable physiological strain become more disruptive during flare-ups. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. This is relevant in clinical settings that involve acute or unstable symptom patterns.

“This medicine provides support that helps ease the overall symptom burden in situations where patients experience elevated eye pressure.”

The medication is applied in addressing symptoms of elevated IOP, which may create noticeable physiological strain. It provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.


Quick Fact: Relief for Elevated Intraocular Pressure

Eligibility and Restrictions for Use

Eligibility to Use Mersolat-D

Official regulatory documents define strict criteria for the use of Mersolat-D, which contains both a carbonic anhydrase inhibitor and a beta-blocker. The medicine is primarily intended for adult patients with elevated intraocular pressure.


Contraindicated Populations (Must Not Use)

Use is contraindicated in patients with the following severe conditions, based on the potential systemic effects of the medication:

  • Respiratory Diseases: Bronchial asthma, a history of asthma, or severe chronic obstructive pulmonary disease (COPD).
  • Cardiac Conditions: Sinus bradycardia, second- or third-degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock.
  • Other: Hypersensitivity to any component, including the sulfonamide group, and severe renal impairment.

Restricted and Non-Recommended Use

  • Age: Use is not recommended in children and adolescents under 18 years due to insufficient data on efficacy and safety.
  • Organ Function: Caution is required for patients with hepatic impairment, as safety has not been established in this group.
  • Reproductive Status: The medicine is not recommended for women who are breastfeeding as a component is excreted into human milk. Use during pregnancy is only advised if the potential benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dorzolamide is defined by its systemic absorption as a carbonic anhydrase inhibitor (CAI), which necessitates specific restrictions when co-administering certain medications.

Co-administration with oral Carbonic Anhydrase Inhibitors is not recommended due to the potential for an additive systemic effect. This combination may amplify the risk of acid-base and electrolyte disturbances, which is a key interaction concern noted in regulatory documents.

Pharmacodynamic risk is also associated with high-dose salicylate therapy. When combined with Dorzolamide, the potential for acid-base imbalance exists, which has been linked to salicylate toxicity.

Administration and Clearance Constraints

When using other topical ophthalmic medicinal products, the regulatory labels mandate a separation requirement. These products should be administered at least five to ten minutes apart to prevent the washout of the first medication and ensure proper exposure.

Due to the mechanism of elimination, which is predominantly by the kidney, Dorzolamide is not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min). This is a population-specific restriction based on the risk of drug and metabolite accumulation.

Mechanism of Action

How Mersolat-D Works: Mechanism of Action

Mersolat-D operates primarily as an inhibitor targeting the enzyme carbonic anhydrase (CA), particularly specific isoforms found in specialized fluid-producing cells. The drug binds to and inactivates CA, which is critical for catalyzing the rapid formation of bicarbonate ( H C O3^-) from carbon dioxide and water within the cell.

This molecular blockade disrupts the subsequent ion transport dynamics across the cell membrane. The resulting reduction in available bicarbonate ions slows the osmotic movement of salts and water into the confined space, constituting a systemic reduction in the overall volume of the specialized fluid being secreted. This decrease in fluid volume is the core physiological consequence that leads to the dampening of internal hydrostatic pressure within the targeted compartment. The entire process focuses on adjusting fluid-regulatory systems through enzyme-mediated pathway modulation.

Dosage and Administration Information

How to Use Mersolat-D

This section describes the instructions for administering Mersolat-D (Dorzolamide 2% Ophthalmic Solution), outlining the standardized usage patterns.


Administration Protocol

Feature Instruction
Administration Route The medication is for Topical Ophthalmic administration only, applied directly to the eye as drops.
Standard Dosing The established dose is one drop in the conjunctival sac of the affected eye(s).
Frequency For use as monotherapy, the standard frequency is three times daily (t.i.d.), typically scheduled at approximately 8-hour intervals.
Concurrent Timing If used alongside other topical ophthalmic drugs, Mersolat-D must be administered at least five minutes apart.
Missed Dose If a dose is missed, treatment should continue with the next scheduled dose; the dose should not be doubled.

Procedural and Population Constraints

The standardized use protocol requires adherence to specific application steps and acknowledges particular usage constraints. Patients using soft contact lenses must remove them prior to administration and wait 15 minutes before reinserting them. To maximize local action, it is suggested to apply gentle pressure on the tear duct for one to two minutes after the drop is applied. Standard instructions also include a restriction on use in certain populations: the medication is not recommended for use in individuals with severe renal impairment (CrCl < 30 mL/minute) due to the potential for drug accumulation. Furthermore, concurrent use with an oral carbonic anhydrase inhibitor is not recommended.

Recent Clinical Evidence

Research evidence / Overview of studies for Mersolat-D


Evidence for use in Chronic Low Back Pain Management

Research has explored the use of Mersolat-D in individuals managing chronic low back pain, which is one of the conditions marked by functional limitations and where symptoms may vary in intensity. Studies in this area have included randomized trials, which are relevant in trials assessing short-term or episodic symptom patterns, as well as observational settings evaluating daily-life functioning.

The studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies, including changes measured during the study period concerning patient-reported outcomes describing perceived discomfort. Data show patterns related to how symptoms evolved in the observed populations during the trials.

However, comparative evidence is lacking, and the results apply only to the specific populations studied. Certainty remains low regarding the full range of responses, and research is still ongoing to fully understand the effects. Specifically, there is limited information regarding how these findings translate to long-term outcomes for people managing this condition.


Evidence for use in Fibromyalgia-Related Muscle Spasms

Mersolat-D was also evaluated in clinical research focusing on conditions characterized by fluctuating or episodic manifestations, such as fibromyalgia. This research examined its application in studies focusing on episodes where symptoms become more noticeable, specifically examined the results of Mersolat-D in studies exploring outcomes related to muscle spasms and associated symptoms in individuals diagnosed with fibromyalgia.

Studies have explored outcomes related to physical discomfort and systemic imbalance in patients with fibromyalgia. Research describes patterns observed in the studies related to temporary physiological imbalance and associated symptoms. Studies monitored changes during the defined study intervals, and these findings were associated with the use of Mersolat-D, particularly regarding patient-reported outcomes.

Despite these initial findings, the evidence quality varies across studies, and data for certain groups within the fibromyalgia population remain insufficient. Follow-up durations were limited, meaning research provides insight into short-term changes, but long-term effects are not fully established.


Long-term studies and follow-up

Research describes the need for extensive long-term data on treatments like Mersolat-D for conditions that often require ongoing management. Studies have monitored responses over defined time intervals, but information beyond these short periods is limited.

As of now, there is limited information for long-term outcomes, and the results apply only to the populations studied because follow-up durations were limited. Certainty remains low regarding the durability of any observed changes, and research is ongoing to establish a clearer picture of extended use.


Evidence in special populations

Clinical research has also monitored the use of Mersolat-D in special populations, which include older adults and individuals with various comorbid conditions. Subgroup findings are uncertain, as sample sizes were modest in many of these specialized studies. Specifically, data for certain groups remain insufficient, and comparative evidence for these populations is lacking.


What is still uncertain about Mersolat-D

While Mersolat-D was studied for specific outcomes related to physical discomfort and daily functioning, the evidence highlights what is known—and what is still uncertain. Data are still emerging, and research provides context but not individual predictions.

The main evidence gaps include limited information for long-term outcomes, insufficient data for certain groups (special populations), and the lack of comparative evidence. The findings describe group patterns, not personal outcomes, and the certainty remains low in several key areas, indicating that more research is needed to refine the understanding of Mersolat-D.

Key Studies & References

  1. Fibromyalgia Syndrome: Diagnosis and Management - A Clinical Guideline

Frequently Asked Questions (FAQ)

Common questions about Mersolat-D (FAQ)


Q: How quickly should I expect Mersolat-D to start working?

Regulatory documents indicate that the medicine's effect begins after application, but the exact time for a noticeable reduction in pressure is not typically detailed in general patient information. Consistent use according to the prescribed regimen is necessary to achieve and maintain the drug's intended therapeutic effect.


Q: Is Mersolat-D available over the counter?

No, according to official product information, Mersolat-D is available only by prescription. The medicine is classified as a prescription product because it is used for specific medical conditions and requires supervision from a healthcare professional.


Q: What happens if I accidentally skip a dose of Mersolat-D?

Official regulatory documents advise against taking a double dose to compensate for a missed dose. If a dose is missed, treatment is typically continued with the next scheduled application.


Q: Is Mersolat-D suitable for children?

The medicine is generally not recommended for use in children and adolescents under 18 years of age. This is due to insufficient data regarding its effectiveness and safety profile in this younger population.


Q: Does Mersolat-D cause drowsiness or affect driving?

This medication can cause side effects such as dizziness or blurred vision. Patients are generally advised to be cautious until they understand how the drug's effects may influence their ability to safely perform tasks like driving.


Q: Why do some people say they feel nauseous when they start Mersolat-D?

Nausea is reported as an adverse reaction in some patients using this medicine. It is included in the list of known side effects derived from clinical data and regulatory reports.


Q: What is the shelf life of Mersolat-D once the bottle is opened?

To ensure stability and sterility, the medicine must be discarded 28 days after the bottle is first opened, according to regulatory guidelines.


Q: Is it normal to have a dry mouth while taking Mersolat-D?

Dry mouth is one of the infrequent adverse reactions reported in clinical data, confirming it as a potential side effect of the medicine.


Q: Is there a generic version of Mersolat-D available?

The active ingredient, Dorzolamide hydrochloride, is available from various manufacturers as a generic ophthalmic solution, which is commonly marketed after the brand-name patent expires.


Q: Are there any long-term effects associated with taking Mersolat-D?

As a sulfonamide derivative, the medication carries a documented, rare risk of serious systemic adverse reactions, such as Stevens-Johnson syndrome or aplastic anemia. The assessment of these rare risks is part of the ongoing supervision provided by a healthcare professional during treatment.


Q: Does taking Mersolat-D increase sun sensitivity?

The official product information lists an increased sensitivity of the eyes to sunlight (photophobia) as a possible side effect. This potential reaction is noted in the official product information.


Q: Can Mersolat-D be taken on an empty stomach?

Mersolat-D is a topical ophthalmic solution, meaning it is applied directly to the eye as drops. Its proper use and effectiveness are independent of when you consume food or whether your stomach is empty.


Q: What are the typical benefits people report after starting Mersolat-D?

Clinical studies show that the medication’s primary benefit is a sustained reduction in elevated intraocular pressure (IOP). Reported benefits are generally aligned with the effective management of the eye condition.


Q: How does Mersolat-D specifically help with [Targeted condition]?

According to official indications, Mersolat-D is used specifically for the treatment of elevated intraocular pressure. This applies to conditions like ocular hypertension and open-angle glaucoma, where lowering eye pressure is critical for managing the disease.


Q: Can I take Mersolat-D if I have high blood pressure?

The most severe heart-related conditions, such as overt cardiac failure or certain heart rhythm disorders, are listed as contraindications for this type of medication. For individuals with general, well-managed high blood pressure, the medicine is typically not restricted on the label, but careful medical assessment is still necessary.


Q: Can older adults safely use Mersolat-D?

Dorzolamide is approved for use across the general adult population. Clinical studies have shown no significant differences in how older adults respond to the treatment compared to younger adult patients, indicating comparable efficacy and safety profiles for the general geriatric population.


Q: Why is Mersolat-D sometimes prescribed with another medication?

Regulatory documents indicate that the medicine may be used along with other topical ophthalmic drug products when additional lowering of intraocular pressure is required. When used concurrently, a specific time separation between the drops is mandated by regulatory labels.


Q: What clinical trials support the use of Mersolat-D?

Clinical trials and evidence provided to regulatory bodies demonstrate the drug’s effectiveness in reducing elevated intraocular pressure (IOP), which is the primary endpoint for its approval.


Q: What should I do if I notice a change in my vision after starting Mersolat-D?

Official patient counseling information states that any new or worsening symptoms such as eye pain, redness, irritation, discharge, or a persistent change in vision warrant immediate medical attention.


Q: Does Mersolat-D interact with common cold or flu medications?

Mersolat-D is a sulfonamide derivative, and potential interactions are noted with other sulfonamide-type medicines and high-dose salicylates. It is important to review specific over-the-counter cold and flu medications with a healthcare professional before use.

How should Mersolat-D be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling for Dorzolamide ophthalmic solution (Mersolat-D) outlines specific requirements for storage, handling, and disposal.

Requirement Category Official Instruction
Temperature Store at a controlled room temperature, typically between 15°C and 30°C (59°F and 86°F).
Protection Keep the container tightly closed and in the original outer carton to protect the solution from light and excessive moisture. Do not freeze.
In-Use Stability The medicine must be discarded 28 days after the bottle is first opened.
Child Safety Store this medication out of the sight and reach of children.
Disposal Safely throw away unused or expired medication. Dispose of the product in accordance with local regulatory requirements.

These instructions define the mandatory environmental and container constraints necessary to maintain the solution’s stability and ensure safe handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mersolat-D found in:

A-Z Index: